Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Clinicopathologic Characteristics And Follow-up Outcomes Of Invasive Breast Carcinoma With Different Positive Her2 Fluorescence In Situ Hybridization Patterns: Experience From A Single Academic Institution

Clinicopathologic Characteristics and Follow-Up Outcomes of Invasive Breast Carcinoma With Different Positive HER2 Fluorescence In Situ Hybridization Patterns: Experience From a Single Academic Institution

Zaibo Li1, Yan Hu1, Dan Jones1

  • 1Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, Ohio.

Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|November 3, 2024

Related Experiment Videos

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

12.6K
Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.0K
Author Spotlight: FISH as a Tool for Precise Gene Amplification Assessment in Cancer Specimens
03:55

Author Spotlight: FISH as a Tool for Precise Gene Amplification Assessment in Cancer Specimens

Published on: July 12, 2024

1.2K

View abstract on PubMed

Summary
This summary is machine-generated.

This study differentiates HER2-positive breast cancer (BC) subtypes using HER2 FISH. High copy number HER2 (G1-HC) BC shows better response to anti-HER2 therapy than low copy number (G1-LC) or group 3 (G3) BC.

Area of Science:

  • Oncology
  • Molecular Pathology
  • Genetics

Background:

  • HER2-positive breast carcinoma (BC) exhibits molecular heterogeneity impacting anti-HER2 therapy response.
  • HER2/CEP17 ratio and HER2 copy number are key determinants in HER2-positive BC classification.
  • Stratification of HER2 fluorescence in situ hybridization (FISH)-positive cases is crucial for understanding treatment efficacy.

Purpose of the Study:

  • To stratify HER2 FISH-positive breast cancer patients into distinct subgroups based on copy number and ratio.
  • To evaluate clinicopathologic features, anti-HER2 therapy response, and outcomes across these subgroups.
  • To provide insights for refining HER2 FISH interpretation criteria.

Main Methods:

  • Retrospective analysis of 2702 primary breast cancer cases.
Keywords:
HER2 FISHHER2 IHCHER2 copy numberHER2/CEP17 ratio

Related Experiment Videos

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

12.6K
Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.0K
Author Spotlight: FISH as a Tool for Precise Gene Amplification Assessment in Cancer Specimens
03:55

Author Spotlight: FISH as a Tool for Precise Gene Amplification Assessment in Cancer Specimens

Published on: July 12, 2024

1.2K
  • Stratification into Group 1 High Copy Number (G1-HC), Group 1 Low Copy Number (G1-LC), and Group 3 (G3) based on HER2 FISH results.
  • Comparison of clinicopathologic characteristics, treatment response, and survival outcomes.

    • Main Results:

    • G1-HC BC (11.3%) showed younger age, higher grade, and ER/PR negativity compared to G1-LC (1.4%) and G3 (2.8%) BC.
    • G1-HC patients demonstrated significantly better response to anti-HER2 neoadjuvant chemotherapy.
    • G1-LC patients had a lower likelihood of disease-free status, but no significant differences in overall survival or recurrence were observed across groups.

    Conclusions:

    • Distinct HER2 FISH subgroups (G1-HC, G1-LC, G3) possess unique clinicopathologic features and differential responses to anti-HER2 therapy.
    • G1-HC BC represents a subgroup with favorable treatment outcomes.
    • Findings support refined HER2 FISH interpretation for personalized breast cancer treatment strategies.
    biomarker
    breast carcinoma